Effectiveness and Safety of Tegafur-Gimeracil-Oteracil Potassium(Ts-1) for Metastatic Breast Cancer

Ishizuna, Kazuo; Kojima, Makoto; Ninomiya, Jun; Kawashima, Miho; Nozaki, Miwako; Shimada, Retsu; Aikawa, Haruhiko; Yamagishi, Hidetsugu; Ogawa, Toshihisa; Oya, Mototsugu

doi:10.1093/annonc/mdu436.20

Cited by 5 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tegafur is a widely used chemotherapy drug in a wide range of cancers, including gastric cancer [30], breast cancer [31], and colorectal cancer [32]. It was reported that tegafur could be used in metastatic gastric cancer; however, it might not enhance the patients' response to fluorouracil-based firstline chemotherapy [33].…”

Section: Discussionmentioning

confidence: 99%

Combination Use of Tegafur and Apatinib as First-Line Therapy in Treatment of Advanced Gastric Cancer: A Single-Blinded Randomized Study

Tang

Wang

2020

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Objective. To investigate the efficacy and safety of the combination use of tegafur and apatinib as a first-line therapy strategy in advanced gastric cancer (GC). Methods. The present study included a total of 62 advanced GC patients. The patients were randomized into the combined group (treated with both tegafur and apatinib) and the control group (treated with only tegafur). Treatment efficacy, KPS score, nutrition condition, and progression-free survival time (PFS) were recorded. Results. Both the response and disease control rates were significantly higher in the combined group. The PFS time was remarkably higher and the KPS score was significantly reduced in the combined group after treatment. After treatment, both groups showed significantly increased nutrition risk, but the rates of patients with nutrition risk or innutrition were remarkably higher in the combined group. The ADR rates were also significantly higher in the combined group. Conclusion. The combination use could achieve good efficacy and prolong patients’ PFS time; however, apatinib also reduced the patients’ quality of life and enhanced the nutrition risk and adverse drug reactions.

show abstract

Section: Discussionmentioning

confidence: 99%

Combination Use of Tegafur and Apatinib as First-Line Therapy in Treatment of Advanced Gastric Cancer: A Single-Blinded Randomized Study

Tang

Wang

2020

Gastroenterology Research and Practice

View full text Add to dashboard Cite

show abstract

“…Tarp paliatyvaus MKV gydymo programų, kurių veiksmingumas įrodytas daugeliu klinikinių tyrimų, svarbios ir schemos, kurias taikant skiriama tablečių formos geriamųjų citostatikų, o būtent kapecitabino ir tegafuro [1][2][3][4]. Pastarieji turi tam tikrų pranašumų, palyginti su infuzinėmis formomis, nes nereikia hospitalizuoti, būdingas silpnesnis hematotoksinis ir emetogeninis toksinis poveikis, nepasireiškia visiškas nuplikimas [1][2][3][4].…”

Section: įVadasunclassified

“…Pastarieji turi tam tikrų pranašumų, palyginti su infuzinėmis formomis, nes nereikia hospitalizuoti, būdingas silpnesnis hematotoksinis ir emetogeninis toksinis poveikis, nepasireiškia visiškas nuplikimas [1][2][3][4]. Pateikti faktai ir klinikiniais tyrimais įrodytas šių preparatų veiksmingumas įgalina juos būti visavertėmis kovos su MKV priemonėmis.…”

Section: įVadasunclassified

See 1 more Smart Citation

Metastazavusio Krūties Vėžio Gydymas Tik Geriamaisiais Chemoterapijos Ir Hormonų Terapijos Preparatais

Timovskaja¹,

Zotovas²,

Anikusko³

2017

Medicinos Teorija Ir Praktika

View full text Add to dashboard Cite

SANTRAUKAReikšminiai žodžiai: metastazavęs krūties vėžys, paliatyvi citostatinė terapija, chemoterapija ir hormonų terapija, periodo be progresavimo trukmė, tegafuras, anastrozolas. Tyrimo tikslas. Palyginti įvairių paliatyvios terapijos schemų efektyvumą, tablečių formos preparatų skyrus hormonų receptorių teigiamam, HER-2/neu neigiamam metastazavusiam krūties vėžiui (MKV) gydyti. Objektas ir metodai. Veikale pateikti 81 MKV sergančios pacientės gydymo rezultatai. Atsitiktinės atrankos būdu tiriamosios buvo suskirstytos į tris grupes ir joms buvo skirta tik tablečių formos preparatų. Pirmosios grupės (A) pacientėms buvo skirta paliatyvi hormonų terapija -aromatazės inhibitoriaus (AI) anastrozolo po 1 mg kasdien. Vieną šios grupės terapijos kursą sudarė 21 diena. Antrosios grupės (C+Ca) pacientėms buvo skirta kapecitabino (2 500 mg/m 2 per parą nuo 8 iki 21 dienos) ir ciklofosfamido (100 mg kasdien nuo 1 iki 14 dienos), esant 21 dienos terapijos ciklui. Trečiosios grupės (T+A) pacientėms buvo skirta tegafuro (1 200-1 600 mg/parą (3-4 kapsulės per parą)) nuo 1 iki 14 dienos (esant 21 dienos terapijos ciklui), derinant su kasdien po 1 mg vartojamu anastrozolu. Buvo nustatoma periodo trukmė be ligos progresavimo -laikas nuo tyrime taikomo gydymo pradžios iki navikinio proceso progresavimo požymių atsiradimo gydant (pagal Kaplano-Mejerio metodą) -ir tiriamos toksinės paskirtos terapijos apraiškos. Rezultatai. Vidutinė periodo be ligos progresavimo trukmė, kartu skyrus chemoterapijos ir hormonų terapijos preparatų tegafuro ir anastrozolo, buvo ilgesnė (15,3 ± 2,1 mėn.) nei skyrus vien tik hormonų terapijos preparato anastrozolo (9,4 ± 1,1 mėn.) arba citostatiko kapecitabino ir ciklofosfamido tablečių derinio (10,0 ± 1,2 mėn.). Pagal Kaplano-Mejerio metodą nustatytas išgyvenamumas be recidyvo buvo geresnis kartu skyrus chemoterapijos ir hormonų terapijos preparatų tegafuro ir anastrozolo nei skyrus tik anastrozolo arba ciklofosfamido ir kapecitabino derinio (p ≤ 0,005). Nepageidaujamų reiškinių dažnis vartojant įvairių paliatyvios terapijos tablečių formos preparatų buvo beveik toks pat. Pasireiškė I-II laipsnio toksinio poveikio nepageidaujamų reiškinių. Išvados. Paliatyvi tablečių formos chemoterapija ir hormonų terapija yra efektyvus hormonų receptorių teigiamo, HER-2/ neu neigiamo MKV gydymo būdas dėl pakankamo efektyvumo, priimtino toksinio poveikio profilio ir galimybės ilgai vartoti preparatus ambulatorinėmis sąlygomis. ABSTRACTKey words: recurrent breast cancer, palliative therapy, cytostatic therapy, chemoendocrine therapy, therapy with tegafur, anastrozole. Aim of the study was to compare the effectiveness of different regimes of palliative therapy using tablet forms of drugs in patients with hormon-dependant Her-2/neu negative recurrent breast cancer who were randomised to three groups and treated exclusively with tablet forms of drugs form of drugs. The first group (A) of patients got palliative endocrine therapy with aromatase inhibitor anastrozole 1 mg daily. For one course of the therapy in this group o...

show abstract

“…OTR primarily remains in the gut due to its low permeability, where it inhibits the production of 5-FU by inhibiting the enzyme orotate phosphoribosyltransferase. [5][6][7] Reduced 5-FU levels in the gut result in less gastrointestinal toxicity. [5] The chemical structures of GMR, TGF, and OTR are depicted in Figure 1.…”

Section: Introductionmentioning

confidence: 99%

Untitled

2023

AJP

View full text Add to dashboard Cite

A trouble-free, simple, specific, and highly sensitive stability indicating phase UPLC method was developed for concurrent assessment of Gimeracil, Oteracil and Tegafur in pure and in their combined tablet formulation. Method: A separation was accomplished by using X-bridge BEH C18 (100 x 2.1 mm, 2.5 µm) column, mobile phase composition of ACN: Buffer (0.5M ammonium formate) (20:80 v/v) and isocratic elution at a flow rate of 0.2 mL/min and detection wavelength of 220nm. The extreme stress conditions like hydrolysis with acid and base, peroxide oxidation, thermal decomposition was used as per ICH specifications to assess the stability of the analytes in bulk and dosage forms. Results and Discussion: The retention times of Gimeracil, Oteracil and Tegafur were found at 1.610, 3.502 and 2.985 min. respectively. The proposed method has linear response in the concentration ranges from 14.5 to 87 µg/mL, 39.5 to 237 µg/mL and 50 to 300 µg/mL of Gimeracil, Oteracil and Tegafur respectively. The LOD and LOQ values were determined as 0.009 μg/mL and 0.026 μg/mL for Gimeracil, 0.23 μg/mL and 0.69 μg/mL for Oteracil and 0.93 μg/mL and 2.81 μg/mL for Tegafur respectively. The acceptance limits of Q2 of the ICH procedures were met by all method validation parameters. The stability of the approach may be seen in the fact that the degradation products from forced degradation tests were well-resolved from Gimeracil, Oteracil and Tegafur. Conclusion: The suggested RP-UPLC method was very sensitive, exact, stable indicator, and cost-effective. Because of this, the method has the potential for use in regular analysis in the quality control department as well as pharmaceutical manufacture of Gimeracil, Oteracil and Tegafur.

show abstract

Effectiveness and Safety of Tegafur-Gimeracil-Oteracil Potassium(Ts-1) for Metastatic Breast Cancer

Cited by 5 publications

References 0 publications

Combination Use of Tegafur and Apatinib as First-Line Therapy in Treatment of Advanced Gastric Cancer: A Single-Blinded Randomized Study

Combination Use of Tegafur and Apatinib as First-Line Therapy in Treatment of Advanced Gastric Cancer: A Single-Blinded Randomized Study

Metastazavusio Krūties Vėžio Gydymas Tik Geriamaisiais Chemoterapijos Ir Hormonų Terapijos Preparatais

Untitled

Contact Info

Product

Resources

About